REFERENCES
1. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016;43:676-81.
2. GLOBOCAN. Cancer Today. Estimated number of new cases in 2020, WHO Europe (EURO), both sexes, all ages. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population-=900&populations=994&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=0&include_nmsc=1&include_nmsc_other=1. [Last accessed on 19 Aug 2021].
3. GLOBOCAN. Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population-=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=0&include_nmsc=1&include_nmsc_other=1. [Last accessed on 19 Aug 2021].
5. de la Puente P, Azab AK. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. Eur J Haematol 2017;98:529-41.
6. Kurtin SE. Relapsed or relapsed/refractory multiple myeloma. J Adv Pract Oncol 2013;4:5-14.
7. Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 2018;8:26.
8. Cancer Research UK, Myeloma incidence statistics 2016. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence. [Last accessed on 19 Aug 2021].
9. GLOBOCAN. Cancer Tomorrow. Estimated number of new cases from 2020 to 2040, Both sexes, age [0-85+] Multiple myeloma and immunoproliferative diseases World. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=35&single_unit=50000&years=2040&group_populations=0&multiple_populations=0&group_cancers=0&multiple_cancers=0. [Last accessed on 19 Aug 2021].
10. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017;14:100-13.
11. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-7.
12. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
13. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582-90.
14. Kovalchuk AL, Mushinski EB, Janz S. Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. Leukemia 2000;14:909-21.
15. Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 2018;132:587-97.
16. Jovanović KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia 2018;32:1295-306.
17. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008:25-31.
18. Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood 2016;128:1735-44.
19. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J 2018;8:7.
20. Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF, Garayoa M. Multiple myeloma mesenchymal stromal cells: contribution to myeloma bone disease and therapeutics. World J Stem Cells 2014;6:322-43.
21. Higgs JT, Lee JH, Wang H, et al. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Adv 2017;1:2375-85.
22. Chae YK, Pan AP, Davis AA, et al. Path toward precision oncology: review of targeted therapy studies and tools to aid in defining "actionability" of a molecular lesion and patient management support. Mol Cancer Ther 2017;16:2645-55.
23. Badalian-Very G. Personalized medicine in hematology - a landmark from bench to bed. Comput Struct Biotechnol J 2014;10:70-7.
24. Schwartzberg L, Kim ES, Liu D, Schrag D. Precision oncology: who, how, what, when, and when not? Am Soc Clin Oncol Educ Book 2017;37:160-9.
25. Shin SH, Bode AM, Dong Z. Precision medicine: the foundation of future cancer therapeutics. NPJ Precis Oncol 2017;1:12.
26. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008;49:615-9.
27. Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018;17:48.
28. NIH NCI. Targeted cancer therapies. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet#what-targeted-therapies-have-been-approved-for-specific-types-of-cancer. [Last accessed on 19 Aug 2021].
30. Fabbro D, Cowan-Jacob SW, Moebitz H. Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol 2015;172:2675-700.
31. Balik K, Modrakowska P, Maj M, Kaźmierski Ł, Bajek A. Limitations of molecularly targeted therapy. Medical Research Journal 2019;4:99-105.
32. Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, Pitson SM. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br J Haematol 2018;182:11-28.
33. Sabnis AJ, Bivona TG. Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol Med 2019;25:185-97.
34. Hann SR. MYC cofactors: molecular switches controlling diverse biological outcomes. Cold Spring Harb Perspect Med 2014;4:a014399.
35. Barrett J, Birrer MJ, Kato GJ, Dosaka-akita H, Dang CV. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol 1992;12:3130-7.
36. Nesbit CE, Grove LE, Yin X, Prochownik EV. Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ 1998;9:731-41.
38. Stefan E, Bister K. . MYC and RAF: key effectors in cellular signaling and major drivers in human cancer. In: Hunter E, Bister K, editors. Viruses, genes, and cancer. Cham: Springer International Publishing; 2017. p. 117-51.
39. Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L. Making decisions through Myc. FEBS Letters 2001;490:153-62.
41. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 2014;4:a014357.
42. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov 2015;5:1024-39.
43. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 1993;7:671-82.
44. Schaub FX, Dhankani V, Berger AC, et al. Cancer Genome Atlas Network. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst 2018;6:282-300.e2.
45. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014;4:a014241.
47. Dominguez-Sola D, Gautier J. MYC and the control of DNA replication. Cold Spring Harb Perspect Med 2014;4:a014423.
50. Tannock I, Hill R, Bristow R, Harrington L. . The basic science of oncology. 5th ed: McGraw-Hill Professional; 2013. p. 588.
51. Holien T, Misund K, Olsen OE, et al. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy. Oncotarget 2015;6:22698-705.
52. Felsher DW, Bishop J. Reversible tumorigenesis by MYC in hematopoietic lineages. Molecular Cell 1999;4:199-207.
53. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin. Molecular Cell 1999;3:565-77.
54. Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW. Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol 2004;14:3-11.
55. Arvanitis C, Felsher DW. Conditionally MYC: insights from novel transgenic models. Cancer Lett 2005;226:95-9.
56. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
57. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002;109:321-34.
58. Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer 2004;110:336-42.
59. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455:679-83.
60. Soucek L, Whitfield JR, Sodir NM, et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 2013;27:504-13.
61. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the 'undruggable' cancer targets. Nat Rev Cancer 2017;17:502-8.
62. Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol 2017;5:10.
63. Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 2002;62:3507-10.
64. Savino M, Annibali D, Carucci N, et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 2011;6:e22284.
65. Massó-Vallés D, Soucek L. Blocking Myc to treat cancer: reflecting on two decades of Omomyc. Cells 2020;9:883.
66. Koh CM, Sabò A, Guccione E. Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays 2016;38:266-75.
67. Gu J, Song S, Han H, et al. The BET bromodomain inhibitor OTX015 synergizes with targeted agents in multiple myeloma. Mol Pharm 2018;15:5387-96.
68. Díaz T, Rodríguez V, Lozano E, et al. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica 2017;102:1776-84.
69. Lim SL, Xu L, Han BC, Shyamsunder P, Chng WJ, Koeffler HP. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. PLoS One 2020;15:e0232068.
70. Stubbs MC, Burn TC, Sparks R, et al. The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. Clin Cancer Res 2019;25:300-11.
71. Falchook G, Rosen S, LoRusso P, et al. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin Cancer Res 2020;26:1247-57.
72. Shapiro GI, LoRusso P, Dowlati A, et al. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer 2021;124:744-53.
73. Ishiguro K, Kitajima H, Niinuma T, et al. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling. Haematologica 2019;104:155-65.
74. Yap TA, Winter JN, Giulino-Roth L, et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res 2019;25:7331-9.
75. Dafflon C, Gaulis S, Barys L, et al. DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway. Oncotarget 2020;11:956-68.
76. Tang S, Ma D, Cheng B, et al. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. Exp Cell Res 2018;363:196-207.
77. Laubach JP, Tuchman SA, Rosenblatt JM, et al. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer J 2021;11:20.
78. Mondala PK, Vora AA, Zhou T, et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell 2021;28:623-36.e9.
79. Das DS, Ray A, Das A, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia 2016;30:2187-97.
80. Cabrales P, Carter C, Oronsky B, Reid T. Rrx-001 is a phase 3 small molecule dual inhibitor of CD47 and Sirpα with activity in multiple myeloma. Blood 2018;132:5623.
81. Zhang Y, Zhou L, Bandyopadhyay D, et al. The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2019;25:6195-205.
82. Czudor Z, Balogh M, Bánhegyi P, et al. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma. Bioorg Med Chem Lett 2018;28:769-73.
83. Hu S, Marineau JJ, Rajagopal N, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res 2019;79:3479-91.
84. Cidado J, Boiko S, Proia T, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res 2020;26:922-34.
85. Sun K, Atoyan R, Borek MA, et al. Dual HDAC and PI3K inhibitor CUDC-907 downregulates MYC and suppresses growth of MYC-dependent cancers. Mol Cancer Ther 2017;16:285-99.
86. Paíno T, Garcia-Gomez A, González-Méndez L, et al. The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care. Clin Cancer Res 2017;23:225-38.
87. Paíno T, González-Méndez L, San-Segundo L, et al. Protein translation inhibition is involved in the activity of the pan-PIM kinase inhibitor PIM447 in combination with pomalidomide-dexamethasone in multiple myeloma. Cancers (Basel) 2020;12:2743.
88. Raab MS, Thomas SK, Ocio EM, et al. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia 2019;33:2924-33.
89. Buettner R, Morales C, Caserta E, et al. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv 2019;3:1027-32.
90. Rosenzweig M, Palmer J, Tsai NC, et al. Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. Leuk Lymphoma 2020;61:1669-77.
91. Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018;36:859-66.
92. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727-38.
93. Mateos MV, Gavriatopoulou M, Facon T, et al. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J Hematol Oncol 2021;14:59.
94. Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol 2021;96:1120-30.
95. Auner HW, Gavriatopoulou M, Delimpasi S, et al. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol 2021;96:708-18.
96. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:1563-73.
97. Itoua Maïga R, Cencic R, Chu J, et al. Oxo-aglaiastatin-mediated inhibition of translation initiation. Sci Rep 2019;9:1265.
98. Grieve S, Wajnberg G, Lees M, et al. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC. Blood Adv 2019;3:3613-25.
99. Ronca R, Ghedini GC, Maccarinelli F, et al. FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. Cancer Res 2020;80:2340-54.
100. Chae YK, Hong F, Vaklavas C, et al. Phase II Study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W. J Clin Oncol 2020;38:2407-17.
101. Yao R, Xie Y, Sun X, et al. Identification of a novel c-Myc inhibitor 7594-0037 by structure-based virtual screening and investigation of its anti-cancer effect on multiple myeloma. Drug Des Devel Ther 2020;14:3983-93.
102. Cao Y, Shan H, Liu M, et al. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell Death Dis 2021;12:396.
103. Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 2018;11:120.
104. Simmons JK, Michalowski AM, Gamache BJ, et al. Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation. Mol Cancer Ther 2017;16:2008-21.
105. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
106. Shi J, Song S, Han H, et al. Potent activity of the bromodomain inhibitor OTX015 in multiple myeloma. Mol Pharm 2018;15:4139-47.
107. Lin X, Huang X, Uziel T, et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol Cancer Ther 2017;16:388-96.
108. Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov 2019;18:609-28.
109. Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov 2018;8:24-36.
110. Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA 2019;5:FSO372.
111. Genta S, Pirosa MC, Stathis A. BET and EZH2 inhibitors: novel approaches for targeting cancer. Curr Oncol Rep 2019;21:13.
112. Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol 2020;11:621093.
113. Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther 2019;4:62.
114. Tu WB, Shiah YJ, Lourenco C, et al. MYC Interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis. Cancer Cell 2018;34:579-95.e8.
115. Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H. EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomark Res 2018;6:34.
116. Vatapalli R, Sagar V, Rodriguez Y, et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nat Commun 2020;11:4153.
117. Ishiguro K, Kitajima H, Niinuma T, et al. Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis. Cell Death Discov 2021;7:7.
118. Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P. Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. Oncotarget 2018;9:23439-42.
119. Caroen S, Oronsky B, Carter C, Lybeck M, Oronsky A, Reid T. Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix. Expert Opin Drug Deliv 2020;17:741-2.
120. Oronsky B, Carter CA, Caroen S, Scribner C, Oronsky A, Reid TR. RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic". Oncoimmunology 2020;9:1746172.
121. Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 2018;131:2661-9.
122. Kelso TW, Baumgart K, Eickhoff J, et al. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol 2014;34:3675-88.
123. Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 2014;159:1126-39.
124. Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014;511:616-20.
125. Chesler L, Schlieve C, Goldenberg DD, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 2006;66:8139-46.
126. Roohi A, Hojjat-Farsangi M. Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. J Drug Target 2017;25:189-201.
127. Pei Y, Liu KW, Wang J, et al. HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell 2016;29:311-23.
128. Chiu H, Buono R, Jackson LV, et al. Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. iScience 2021;24:102748.
129. Mougiakakos D, Bach C, Böttcher M, et al. The IKZF1-IRF4/IRF5 axis controls polarization of myeloma-associated macrophages. Cancer Immunol Res 2021;9:265-78.
130. Pal I, Safari M, Jovanovic M, Bates SE, Deng C. Targeting translation of mRNA as a therapeutic strategy in cancer. Curr Hematol Malig Rep 2019;14:219-27.
131. Taroncher-Oldenburg G, Müller C, Obermann W, Ziebuhr J, Hartmann RK, Grünweller A. Targeting the DEAD-Box RNA helicase eIF4A with Rocaglates-A pan-antiviral strategy for minimizing the impact of future RNA virus pandemics. Microorganisms 2021;9:540.
132. Sun XX, He X, Yin L, Komada M, Sears RC, Dai MS. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc Natl Acad Sci U S A 2015;112:3734-9.
133. Huang HL, Weng HY, Wang LQ, et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther 2012;11:1155-65.
134. Yang D, Hurley LH. Structure of the biologically relevant G-quadruplex in the c-MYC promoter. Nucleosides Nucleotides Nucleic Acids 2006;25:951-68.
135. Brooks TA, Hurley LH. Targeting MYC Expression through G-Quadruplexes. Genes Cancer 2010;1:641-9.
136. Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem 2011;286:41018-27.
137. Ferreira R, Schneekloth JS Jr, Panov KI, Hannan KM, Hannan RD. Targeting the RNA polymerase I transcription for cancer therapy comes of age. Cells 2020;9:266.
138. Khot A, Brajanovski N, Cameron DP, et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. Cancer Discov 2019;9:1036-49.
139. Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB. Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor. J Control Release 2018;286:1-9.
140. Calabrese DR, Chen X, Leon EC, et al. Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. Nat Commun 2018;9:4229.
141. Gaikwad SM, Phyo Z, Arteaga AQ, et al. A small molecule stabilizer of the MYC G4-quadruplex induces endoplasmic reticulum stress, senescence and pyroptosis in multiple myeloma. Cancers (Basel) 2020;12:2952.
142. Minard A, Morgan D, Raguseo F, et al. A short peptide that preferentially binds c-MYC G-quadruplex DNA. Chem Commun (Camb) 2020;56:8940-3.
143. Webb MS, Tortora N, Cremese M, et al. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev 2001;11:155-63.
144. Arora V, Knapp DC, Smith BL, et al. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther 2000;292:921-8.
145. Wang H, Mannava S, Grachtchouk V, et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008;27:1905-15.
146. Tolcher AW, Papadopoulos KP, Patnaik A, et al. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. JCO 2015;33:11006.
147. Morelli E, Biamonte L, Federico C, et al. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood 2018;132:1050-63.
148. Caracciolo D, Scionti F, Juli G, et al. Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. Haematologica 2021;106:185-95.
149. Sorolla A, Wang E, Golden E, et al. Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene 2020;39:1167-84.
150. Berg T, Cohen SB, Desharnais J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 2002;99:3830-5.
151. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003;22:6151-9.
152. Fletcher S, Prochownik EV. Small-molecule inhibitors of the Myc oncoprotein. Biochim Biophys Acta 2015;1849:525-43.
153. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem 2007;2:627-30.
154. Hart JR, Garner AL, Yu J, et al. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A 2014;111:12556-61.
155. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci U S A 2006;103:6344-9.
156. Jeong KC, Kim KT, Seo HH, et al. Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth. J Urol 2014;191:510-8.
157. Giorello L, Clerico L, Pescarolo MP, et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 1998;58:3654-9.
158. Beaulieu ME, Jauset T, Massó-Vallés D, et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med 2019;11:eaar5012.
